UNRESECTABLE MALIGNANT SOLID NEOPLASM
Clinical trials for UNRESECTABLE MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for UNRESECTABLE MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of three drugs (copanlisib, olaparib, and durvalumab) in people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to find the safest dose and see if the drugs shrink tumors. About 39 adults with spe…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:40 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed by surgery. The stud…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:38 UTC
-
New combo attack on Hard-to-Treat cancers shows early promise
Disease control OngoingThis early-phase trial tests a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (which blocks a DNA repair enzyme)—in people with advanced solid tumors that have a HER2 mutation. The goal is to find the safest dose and see if the combo wo…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:37 UTC
-
Promising combo targets Hard-to-Treat HER2 cancers
Disease control TerminatedThis early-phase trial tests the safety and best dose of combining two drugs—neratinib and trastuzumab deruxtecan—for people with advanced solid tumors that have HER2 gene changes and have spread or can't be surgically removed. The goal is to see if the combination can shrink tum…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:36 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that have specific genetic mutations. The goal was to find the best dose and check for side effects. The approach aims to shrink or stabilize tumor…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:26 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 06:25 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study is for people with advanced solid tumors that have specific gene changes (KRAS or NRAS mutations) and have not responded to standard treatments. It tests two drugs: trametinib, which blocks a protein that helps cancer grow, and navitoclax, which blocks proteins that ke…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:23 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in adults with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 participants with…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Triple attack on tough tumors: drug combo plus radiation shows promise
Disease control OngoingThis study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation for people with advanced solid tumors or bile duct cancers that have spread. The goal is to find the best dose and see if the treatment can shrink tumors or stop them from growi…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug cocktail aims to starve and shrink Hard-to-Treat cancers
Disease control OngoingThis early-phase study tested a combination of two drugs, cediranib and selumetinib, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could block tumor growth by cutting off blood…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New combo therapy targets Hard-to-Treat cancers with genetic mutations
Disease control TerminatedThis study tests whether adding a targeted drug (ipatasertib) to standard chemotherapy (paclitaxel) can shrink or slow advanced solid tumors that have PTEN or AKT gene changes. About 33 adults with cancers that have spread or can't be removed by surgery will take part. The goal i…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Personalized cell therapy trial for advanced cancers withdrawn before enrollment
Disease control TerminatedThis early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy aims to boost immune attack on tumors
Disease control OngoingThis early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Experimental combo aims to shrink Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called copanlisib combined with immunotherapy drugs (nivolumab, with or without ipilimumab) in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The goal is to find a dose t…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Targeted drug shows promise for rare, Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called telaglenastat (CB-839) in adults with advanced solid tumors or malignant peripheral nerve sheath tumors that have certain gene mutations (NF1, KEAP1/NRF2, or LKB1). The drug works by blocking an enzyme cancer cells need to grow. Researchers want to …
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial studies the safety and best dose of combining two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have spread or cannot be removed. The goal is to see if the combination can help the immune syste…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New drug cocktail targets Hard-to-Treat cancers with gene mutations
Disease control OngoingThis study tests a combination of three drugs (copanlisib, nivolumab, and ipilimumab) in adults with advanced solid tumors that have specific gene changes (PIK3CA or PTEN). The goal is to see if adding copanlisib to standard immunotherapy works better at controlling tumor growth.…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
New combo targets Cancer's DNA repair weakness
Disease control OngoingThis study tests a combination of two drugs (avelumab and M6620) in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see how well the drugs work together t…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New drug DS-8201a shows promise in targeting Hard-to-Treat cancers
Knowledge-focused OngoingThis early-phase trial looks at how DS-8201a works in patients with advanced HER2-positive solid tumors that have spread or cannot be removed. The drug targets a protein on cancer cells to damage their DNA and kill them. Researchers will compare tumor samples taken before and aft…
Matched conditions: UNRESECTABLE MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 26, 2026 06:25 UTC